FDA clears Lilly's COVID-19 antibody cocktail for emergency use

Bio Pharma Dive

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

F.D.A. Authorizes Another Antibody Treatment

NY Times

internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.

U.S. Buys 100,000 Doses of an Eli Lilly Antibody Treatment

NY Times

internal-essential Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Eli Lilly and CompanyThe government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.

Boehringer goes after antibody cancer drugs in latest acquisition

Bio Pharma Dive

billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020

Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugs

Bio Pharma Dive

The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers

Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug

Bio Pharma Dive

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Bio Pharma Dive

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.

AZ deploys mobile sites to test COVID-19 antibody AZD7442

Pharma Phorum

AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims to narrow the gap with the help of decentralised clinical trial specialist Care Access Research. The post AZ deploys mobile sites to test COVID-19 antibody AZD7442 appeared first on.

LSBio Acquires Absolute Antibody Ltd.

BioTech 365

LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.

Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study

Bio Pharma Dive

The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19

Eli Lilly’s Dual Antibody Bamlanivimab and Etesevimab Treatment Lowers Risk of COVID-19 Hospitalizations and Deaths

XTalks

Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent.

Can new Regeneron, Lilly data move the needle for COVID-19 antibody drugs?

Bio Pharma Dive

The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Pharma Phorum

According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19.

What to Know of Covid-19 Antibody Drugs: Cost, Availability and More

NY Times

Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Eli Lilly and Company Regeneron Pharmaceuticals Inc Food and Drug Administration Antibodies your-feed-healthcareHere’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.

ImmunoPrecise Antibodies Announces Grant of Stock Options

BioTech 365

ImmunoPrecise Antibodies Announces Grant of Stock Options ImmunoPrecise Antibodies Announces Grant of Stock Options VICTORIA, British Columbia–(BUSINESS WIRE)–$IPA #POLYTOPE–IMMUNOPRECISE ANTIBODIES LTD. (“IPA”

Companies Press Ahead with COVID-19 Antibody Therapies

BioSpace

Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease

Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktail

Pharma Phorum

The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infections. The two antibodies were discovered by Vanderbilt University Medical Center and licensed to AZ in June.

Salk team reveals never-before-seen antibody binding, informing liver cancer, antibody design

Scienmag

Multi-institute collaboration uses X-ray crystallography and recombinant antibodies to uncover workings of an elusive molecule central to human health Credit: Salk Institute LA JOLLA–(February 17, 2021) In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

BioTech 365

Lilly’s antibodies bamlanivimab and etesevimab show promise against COVID-19

Pharma Times

Neutralising antibodies significantly reduced COVID-19-related hospitalisations and deaths

US buys Lilly COVID antibody, as effectiveness questions remain

Pharma Phorum

Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As These institutions are best positioned to direct our antibody treatments to the patients who need them most.”.

Antibodies, Immunity, and COVID-19

JAMA Internal Medicine

Widespread availability of commercial assays that detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine naturally acquired immunity to coronavirus disease 2019 (COVID-19) at the population level. The study uses national data to expand on an earlier US Centers for Disease Control and Prevention study of seroprevalence of antibodies to SARS-CoV-2 in 10 US sites

Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment

BioTech 365

Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment EXTON, Pa. &

Regeneron’s Antibody Drug Becomes First Approved Treatment for Ebola

XTalks

Inmazeb is a combination of three different antiviral monoclonal antibodies. The three monoclonal antibodies contained in Inmazeb are of similar structure; however, they bind to different, non-overlapping epitopes simultaneously on a glycoprotein found on the surface of the Ebola virus.

Lilly's antibody drug prevents COVID-19 in study, but hurdles to use remain

Bio Pharma Dive

Results from a clinical trial in nursing home residents and staff offered the first evidence Lilly's bamlanivimab could protect against, as well as treat, COVID-19

Nurses 194

UK biotech consortium identifies COVID-19 antibody combinations

Pharma Times

The UK BIA Antibody Taskforce is set to take combinations into further development as a cocktail

Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination

Fujifilm to help Lilly make COVID-19 antibody drug

Bio Pharma Dive

Lilly has asked the FDA for emergency clearance of the therapy, although a study safety review and an unrelated manufacturing inspection could complicate the request

AbbVie begins trials of COVID-19 antibody therapy

Pharma Phorum

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. The pharma will also pay tiered royalties on commercial net sales of the antibody.

Scientists reveal details of antibodies that work against Zika virus

Scienmag

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibodies recognize and attack different SARS-CoV-2 spike shapes

Scienmag

The spikes on the SARS-CoV-2 virus, which causes COVID-19, change shapes; new research reveals ways that antibodies can recognize these different shapes and block the virus and informs the design of vaccines and antiviral therapies Credit: Image courtesy of Wenwei Li.

US pushes for wider use of 'underutilized' COVID-19 antibody drugs as pandemic worsens

Bio Pharma Dive

billion deal with Regeneron this week is part of a renewed effort by government officials to bolster uptake of the treatments, which haven't gained traction

UPMC Researchers Isolate Tiny Antibody That Neutralizes SARS-CoV-2 Virus

BioSpace

The researchers used this antibody, which is 10-times smaller than a full-sized antibody and the smallest isolated biological molecule to date, to develop a potential therapeutic and prophylactic agent against the virus termed “Ab8

Lilly offers first evidence that its antibody drug may help treat COVID-19

Bio Pharma Dive

The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear

Roche Launches New COVID-19 Antibody Test to Support Vaccine Testing

BioSpace

Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark

Antibody response may drive COVID-19 outcomes

Scienmag

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults. BOSTON — COVID-19, the source of the current pandemic, may be caused by a single virus, but it has a variety […]. Infectious Emerging Diseases Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Pediatrics Vaccines

U.S. Government Inks Antibody Cocktail Deal with AstraZeneca

BioSpace

government program to advance COVID-19 vaccines and therapeutics, for a monoclonal antibody cocktail AstraZeneca signed a deal with Operation Warp Speed, the U.S.